Abstract:533 Background: Cholangiocarcinoma (CC) is an aggressive malignancy with an all stage 5-year survival rate of less than 15%. Preclinical research is of pivotal importance to acquire a deeper understanding of CC and improve outcomes. The establishment of CC organoids has previously been described to be difficult due to fewer driver mutations and limitations in the ability to mimic tumor microenvironment. The aim of this study was to develop a successful culturing system for CC organoids that preserves intratumoral heterogeneity, and in turn, to determine the feasibility of personalized medicine in patients with CC using organoids. Methods: From 2020-2023, 75 CC tumor samples were prospectively collected from 65 patients. The tumors were sequenced using MSK-IMPACT, a targeted next generation sequencing (NGS) platform. Samples were processed, and organoids were generated and cultured following a standardized protocol. The organoids were grown in three different types of enriched media (M1, M2, and M3). Once cultures were adequately expanded, organoid lines were sequenced using MSK-IMPACT and/or MiSeq, a benchtop NGS platform. Mutations of the organoid line were compared to that of the tumor of origin to determine tumor enrichment. To ascertain genotypic association with organoid formation, we examined frequencies of driver mutations of interest. Logistic regression was used to assess the univariate association between mutations of interest and organoid establishment. Two-sided p-values less than 0.05 were considered to be significant. Results: Of the 75 samples collected, 24 (32%) were extrahepatic CC tumors, and the remaining were of intrahepatic origin. 92% of the samples were collected from primary tumors, and 71% of the samples were chemotherapy naïve. 64 samples successfully grew organoids. Upon evaluation of MSK-IMPACT and MiSeq data, 11 of the 64 samples were noted to retain the mutations of the tumor of origin in organoid culture; the overall success rate of tumor organoid formation was 14.6% (11/75). Tumor enrichment of organoid lines was most commonly achieved using M3 (9 out of 11 samples), the median passage at which tumor enrichment occurred was 8 (interquartile range (IQR) 2-10), indicating that the approximate median time to tumor organoid formation was 16 weeks (IQR 4-20 weeks). There was no statistically significant association between driver mutations and organoid establishment. Conclusions: Intratumoral heterogeneity of cholangiocarcinoma is maintained in organoid culture. This preclinical model potentially recapitulates the clinical features of the disease seen in humans. However, prolonged duration and low success rate of tumor enrichment makes it a less appealing avenue for personalized medicine.

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening

Gastric cancer patient-derived organoids model for the therapeutic drug screening

Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models

Integrated Characterization of Hepatobiliary Tumor Organoids Provides a Potential Landscape of Pharmacogenomic Interactions

Patient-derived biliary tract cancer organoid biobank: Is personalized medicine utilizing organoids feasible for patients with cholangiocarcinoma?

Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening

Establishment and Drug Screening of Patient-Derived Extrahepatic Biliary Tract Carcinoma Organoids

Characteristics of a Novel Cell Line ZJU-0430 Established from Human Gallbladder Carcinoma

Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing

Establishment of patient-derived organoids and a characterization based drug discovery platform for treatment of gastric cancer

Modeling bladder cancer in the laboratory: Insights from patient-derived organoids

Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Intrahepatic cholangiocarcinoma-derived organoids for disease modelling and drug screening

Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer

IDDF2022-ABS-0105 Patient-derived Organoids Can Predict Chemotherapy Response of Gastric Cancers and Analysis of Its Molecular Characteristics

Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro

Abstract 191: CTC-derived organoids from liver and pancreatic cancer patients for personalized therapy

Multicellular 3D bioprinted human gallbladder carcinoma for in vitro mimicry of tumor microenvironment and intratumoral heterogeneity

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids As a Platform for Drug Screening